MDRP 2012 Session Spotlight: Potential Impact of the Proposed Rule and 340B Program Updates

There is no pharmaceutical or generic manufacturer not impacted by the rules set forth by CMS and OPA. While the government representatives might not be able to discuss ongoing proposed rules themselves, the updates to the 340B program and the AMP Proposed Rule are still the most talked about topics this year and we have the most respected industry leaders on hand to discuss what these potential new rules mean to your company in 2013 and beyond.  Join us at Medicaid Drug Rebate Program Summit 2012 for the session "Potential Impact of the Proposed Rule and 340B Program Updates" to go in-depth on this topic with expert Alice Valder Curran, Partner, Hogan Lovells US LLP.

For more information the Medicaid Drug Rebate Program Summit, download the brochure.  If you'd like to join us September 10-12 in Chicago, register today! As a reader of this blog, when you mention code XP1758BLOG, you'll receive a discount of 25% off the standard rate.

Featured Session: Potential Impact of the Proposed Rule and 340B Program Updates
Featured Speaker: Alice Valder Curran, Partner, HOGAN LOVELLS US LLP
About the session: Now that you’ve heard the policy and operational updates from CMS and OPA, you will want to stay and hear how to put all of this information into practice at your company. This session will detail the hottest topics in the industry up until the last minute and how they will affect your company.